ABP2111

Primary purpose: To evaluate the safety and tolerability of single and multiple oral administration of ABP2111Na tablets in patients with type 2 diabetes, and to recommend the dosage range for the study of this product in patients with type 2 diabetes in phase II; Secondary purpose: 1) To evaluate the pharmacokinetic (PK) characteristics of single and multiple oral administration of ABP2111Na tablets in patients with type 2 diabetes; 2) To evaluate the pharmacodynamic (PD) characteristics of single and multiple oral administration of ABP2111Na tablets in patients with type 2 diabetes. Exploratory purpose: To preliminarily evaluate the effectiveness of oral administration of ABP2111Na tablets in patients with type 2 diabetes; To evaluate the cardiac safety of ABP2111Na tablets in patients with type 2 diabetes in the high-dose group.

Main purpose: Evaluate the safety and tolerability of ABP2111Na tablets after multiple oral administration in overweight/obese subjects; Secondary purposes: 1) Evaluate the pharmacokinetic (PK) characteristics of ABP2111Na tablets after multiple oral administration in overweight/obese subjects; 2) Evaluate the pharmacodynamics (PD) of ABP2111Na tablets after multiple oral administration in overweight/obese subjects; 3) Preliminarily explore the effectiveness of ABP2111Na tablets in controlling body weight and provide a basis for later clinical studies; 4) Preliminarily evaluate the cardiac safety of ABP2111Na tablets in overweight/obese subjects, including the possibility of correcting the QT interval (QTc) prolongation, and evaluate the PK/QTc relationship.